Clinical trial NCT00663000 - References

Diabetes — Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance

Citation(s)

•   Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB
  Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998 Oct;83(10):3411-8.
•   Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A
  Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998 Feb;83(2):374-8.
•   Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA
  Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999 May;50(5):561-7.
•   Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM
  Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997 Oct;82(10):3187-91.
•   Bates AS, Van't Hoff W, Jones JM, Clayton RN
  An audit of outcome of treatment in acromegaly. Q J Med. 1993 May;86(5):293-9.
•   Biermasz NR, van Dulken H, Roelfsema F
  Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000 Jul;85(7):2476-82.
•   Caron P, Tabarin A, Cogne M, Chanson P, Jaquet P
  Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications. Eur J Endocrinol. 2000 Jun;142(6):565-71.
•   Clemmons DR
  Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary. 2002;5(3):181-3. Review.
•   Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G
  Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006 Mar;154(3):467-77.
•   Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM
  Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf). 1998 Mar;48(3):311-6. Erratum in: Clin Endocrinol (Oxf) 1998 May;48(5):673.
•   Eastman RC, Gorden P, Glatstein E, Roth J
  Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 1992 Sep;21(3):693-712. Review.
•   Elmlinger MW, Kühnel W, Weber MM, Ranke MB
  Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med. 2004;42(6):654-64.
•   Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG
  Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994 Sep;73(5):233-40.
•   Fahlbusch R, Honegger J, Buchfelder M
  Evidence supporting surgery as treatment of choice for acromegaly. J Endocrinol. 1997 Oct;155 Suppl 1:S53-5.
•   Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ
  Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005 May 7-13;365(9471):1644-6. Erratum in: Lancet. 2005 May;365(9471):1620.
•   Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ
  Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol. 2006 Jun;154(6):805-6.
•   Fløgstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J
  Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab. 1997 Jan;82(1):23-8.
•   Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S
  Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000 Feb;85(2):526-9. Review.
•   Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R
  Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol. 1986 Mar;250(3 Pt 1):E269-73.
•   Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS
  Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion. Clin Endocrinol (Oxf). 1999 Feb;50(2):245-51.
•   Jaffe CA, Barkan AL
  Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992 Sep;21(3):713-35. Review.
•   Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H
  Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005 Oct;90(10):5627-31. Epub 2005 Jul 26.
•   Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC
  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.
•   Melmed S
  Acromegaly. N Engl J Med. 1990 Apr 5;322(14):966-77. Review.
•   Møller N, Schmitz O, Jøorgensen JO, Astrup J, Bak JF, Christensen SE, Alberti KG, Weeke J
  Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab. 1992 May;74(5):1012-9.
•   Orme SM, McNally RJ, Cartwright RA, Belchetz PE
  Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998 Aug;83(8):2730-4.
•   Osman IA, James RA, Chatterjee S, Mathias D, Kendall-Taylor P
  Factors determining the long-term outcome of surgery for acromegaly. QJM. 1994 Oct;87(10):617-23.
•   Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK
  Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994 Jul;41(1):95-102.
•   Rose DR, Clemmons DR
  Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res. 2002 Dec;12(6):418-24.
•   Saccà L, Cittadini A, Fazio S
  Growth hormone and the heart. Endocr Rev. 1994 Oct;15(5):555-73. Review.
•   Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ; German Pegvisomant Investigators
  Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007 Jan;156(1):75-82.
•   Stumvoll M, Van Haeften T, Fritsche A, Gerich J
  Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care. 2001 Apr;24(4):796-7.
•   Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT
  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26.
•   Sze L, Schmid C, Bloch KE, Bernays R, Brändle M
  Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol. 2007 Mar;156(3):321-9.
•   Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA
  Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg. 1993 Feb;78(2):205-15.
•   van der Lely AJ, de Herder WW, Lamberts SW
  A risk-benefit assessment of octreotide in the treatment of acromegaly. Drug Saf. 1997 Nov;17(5):317-24. Review.
•   van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW
  Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab. 2001 Feb;86(2):478-81.
•   Veysey MJ, Thomas LA, Mallet AI, Jenkins PJ, Besser GM, Wass JA, Murphy GM, Dowling RH
  Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Gut. 1999 May;44(5):675-81.
•   Wasada T, Aoki K, Sato A, Katsumori K, Muto K, Tomonaga O, Yokoyama H, Iwasaki N, Babazono T, Takahashi C, Iwamoto Y, Omori Y, Hizuka N
  Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy. Endocr J. 1997 Aug;44(4):617-20.

Observational, Cross-sectional, Longitudinal, Multi-center, Diagnostic Study to Evaluate the Influence of Acromegaly on Glucose Tolerance and to Evaluate the Changes of Impaired Glucose Tolerance During Standard Treatment of Acromegaly.

Details for clinical trial NCT00663000